Kornimate/medical-research-clean huggingface dataset:
tension-free-vaginal-tape-obturator (tvto) versus tension-free-vaginal-tape-secur (tvts) for treatment of sui

Conditions: Urinary Stress Incontinence

Summary: women with urinary stress incontinence who underwent surgical treatment by either tvto or tvts will be enrolled. the investigators will collect data from charts and use a telephone questionnaire to check the outcome of these women. physical examination findings will also be incorporated.


Eligibility criteria:
inclusion criteria: * women with usi who underwent tvts or tvto procedure, more than 6 months ago exclusion criteria: * women who have not undergone tvt procedure

Keywords: urinary stress incontinence tvt
helping olfaction and nutrition on renal replacement

Conditions: End Stage Renal Disease; Olfactory Disorders

Summary: this clinical trial examines whether nasal theophylline administration can improve olfaction and nutrition in hemodialysis patients.

malnutrition and cachexia are prevalent in end stage renal disease (esrd) patients and are associated with increased morbidity and mortality. food aversion is a major contributor to anorexia and malnutrition in esrd and it also impacts the quality of life. olfactory dysfunction has been shown to contribute to food aversion in esrd patients. since up to 80% of a meal's flavor is attributed to olfactory input, loss or alteration of smell leads to loss or alteration of taste in esrd patients and at present there are no effective therapies to treat smell and/or taste disorders in esrd patients. in patients with other causes of olfactory dysfunction such as congenital hyposmia and traumatic brain injury, intranasal theophylline has been shown to be effective in improving olfactory defects via increasing nasal mucus levels of camp and cgmp, second messengers critical for optimal smell sensation. however, the efficacy of nasal theophylline to improve olfaction in esrd patients has not been investigated and the effects of nasal theophylline treatment on the nutritional parameters are unknown in esrd patients. aim: to examine the efficacy and safety of nasal theophylline treatment to improve olfaction and nutrition in esrd patients hypothesis: nasal theophylline treatment improves olfaction and nutrition in esrd patients with olfactory defects by via increasing intracellular camp and cgmp levels. a previous pilot clinical trial demonstrated that intranasal theophylline is safe and effective in improving olfactory deficits in congenital hyposmia and traumatic brain injury, however, it has not been examined in esrd patients. the investigators will conduct a pilot single arm open-label clinical trial (n=20) of 6 weeks duration to examine the efficacy and safety of nasal theophylline in hemodialysis-dependent esrd patients with olfactory defects. the investigators will examine whether nasal theophylline improves olfaction and nutritional status in trial participants.

Eligibility criteria:
inclusion criteria: * esrd requiring chronic outpatient hemodialysis * able to provide written consent * defects in smell identification and/or smell threshold detection as measured by "scratch-and-sniff" university of pennsylvania smell identification test (upsit) and smell threshold test exclusion criteria: * prior allergic reaction to theophylline * patients currently treated with theophylline for clinical indication * pregnancy or lactation * esrd patients on peritoneal dialysis * patients hospitalized at the time of study enrollment

Keywords: end stage renal disease olfaction dialysis hemodialysis malnutrition
different radiation dose of neoadjuvant chemoradiation for resectable thoracic esophageal squamous carcinoma

Conditions: Esophageal Carcinoma; Neoadjuvant Chemoradiotherapy; Surgery

Summary: esophageal cancer is one of the most common cancers worldwide, while more than half new cases and deaths occurred in china. surgery is the main curative treatment for this disease, the 5-year survival of ec remains poor, since most diseases are diagnosed at advanced stages. in last decades, several large clinical trials and meta-analyses have demonstrated that neo-adjuvant chemoradiotherapy followed by surgery can significantly increase the overall survival of patients with ec compared with surgery alone, while no effect of ncrt was apparent on postoperative health-related quality of life . however, the optimal radiation dose and surgery timing are still unknown. the investigators hypothesize that patients who receive higher dose (50.4gy/28f) of neoadjuvant chemoradiation will have better pathologic response and progress-free survival compared to lower dose (41.4gy/23f) of chemoradiation followed by surgery.


Eligibility criteria:
inclusion criteria: age:18-70 years histologically verified squamous carcinoma of the thoracic esophagus. patients with performance status 0-1 according to the eastern cooperative oncology group (ecog) scale at the pre crt evaluation and judges to be fit for surgery at the pre and post crt evaluations. tumors should be resectable or potentially resectable and without distant metastasis, as assessed before neoadjuvant crt, including clinical stage t2-4n0m0 or t1-4n1m0 according to the 6th ajcc system. joined the study voluntarily and signed informed consent form no surgical contraindications no serious system dysfunction and immuno-deficiency, adequate organ function including the following: hemoglobin ≥10 g/dl, neutrophils (anc )≥1.5x109/l, platelet count ≥100x 109/l, tbil\<1.5 x uln, alt and ast ≤ 2.5 x uln, creatinine≤1.5 x uln exclusion criteria: cervical esophageal cancer (the upper end of the lesion is in the esophagus of the cervical segment). patients with biopsy (by endoscopic ultrasound, laparoscopy, or laparotomy) proven metastatic supraclavicular or celiac nodes are ineligible. invasion of the tracheobronchial tree or aorta tracheoesophageal fistula concurrent pregnancy or lactation severe diabetes mellitus with poor blood glucose control history of a second malignancy patients being unable to undergo esophageal reconstruction with gastric tube, due to prior surgery. patients undergoing esophageal reconstruction with jejunum. patients have allergy reaction or contraindications to taxanes.

Keywords: radiation dose
docetaxel and carboplatin versus docetaxel as second line treatment in patients with non-small-cell lung carcinoma (nsclc)

Conditions: Non-Small Cell Lung Cancer

Summary: this trial will compare the effectiveness of docetaxel with or without carboplatin as second line chemotherapy in patients with non-small cell lung cancer, who have not been treated previously with docetaxel.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed nsclc. * ecog performance status 0-2. * no previous treatment with docetaxel. * measurable disease. * brain metastases that have been treated with radiotherapy should be stable and asymptomatic. * adequate liver kidney and bone marrow function. * patients must be able to understand the nature of this study and give written informed consent. exclusion criteria: * active cardiac disease: unstable angina or onset of angina within last 3 months, myocardial infarction within 6 months, congestive heart failure \> class ii, cardiac ventricular arrhythmias requiring anti-arrhythmic therapy. * women who are pregnant or lactating. * unknown hiv, chronic hepatitis b or chronic hepatitis c infections. * serious neurologic or psychiatric disease. * second primary malignancy within the past 5 years, except nonmelanomas skin cancer or in situ carcinoma of the cervix. * active uncontrolled infection.

Keywords: non small cell lung cancer 2nd line chemotherapy docetaxel
a study of once monthly bonviva (ibandronate) in prevention of glucocorticoid-induced osteoporosis.

Conditions: Postmenopausal Osteoporosis

Summary: this 2 arm study will investigate the efficacy and safety of bonviva (150mg po monthly) in the prevention of glucocorticoid-induced osteoporosis in post-menopausal women. patients will be randomized to receive either bonviva 150mg po or placebo monthly, with vitamin d and calcium supplementation. the anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * post-menopausal women, 50-85 years of age; * any inflammatory rheumatoid disease including polymyalgia rheumatica; * receiving treatment with 5-15 mg/day of prednisolone. exclusion criteria: * previous treatment with an iv bisphosphonate at any time; * previous treatment with an oral bisphosphonate within the last 6 months, \>1 month of treatment within last year, or \>3 months of treatment within last 2 years; * treatment with parathyroid hormone in last 2 years; * inability to stand or sit in an upright position for at least 60 minutes; * inability to swallow a tablet whole; * history of major gastrointestinal disease.
automated phonocardiography analysis in adults

Conditions: Aortic Insufficiency; Aortic Stenosis; Mitral Insufficiency; Mitral Insufficiency and Aortic Stenosis; Tricuspid Regurgitation; Insufficiency, Pulmonary; Insufficiency, Tricuspid

Summary: background: computer aided auscultation in the differentiation of pathologic (aha class i) from no- or innocent murmurs (aha class iii) via artificial intelligence algorithms could be a useful tool to assist healthcare providers in identifying pathological heart murmurs and may avoid unnecessary referrals to medical specialists. objective: assess the quality of the artificial intelligence (ai) algorithm that autonomously detects and classifies heart murmurs as either pathologic (aha class i) or as no- or innocent (aha class iii). hypothesis: the algorithm used in this study is able to analyze and identify pathologic heart murmurs (aha class i) in an adult population with valve defects with a similar sensitivity compared to medical specialist. methods: each patient is auscultated and diagnosed independently by a medical specialist by means of standard auscultation. auscultation findings are verified via gold-standard echocardiogram diagnosis. for each patient, a phonocardiogram (pcg) - a digital recording of the heart sounds - is acquired. the recordings are later analyzed using the ai algorithm. the algorithm results are compared to the findings of the medical professionals as well as to the echocardiogram findings.


Eligibility criteria:
inclusion criteria: * adults with a heart defect verified by echocardiography
kidney yin/yang replenishment on patients with renal osteodystrophy

Conditions: Renal Insufficiency, Chronic; Renal Osteodystrophy

Summary: patients with serious chronic renal insufficiency usually develop secondary osteoporosis or bone loss, especially those with chronic dialysis, and the degree of bone loss is corrected with decrease of renal function. in traditional chinese medicine, kidney function is considered to dominate bone development and metabolism. kidney yin and yang replenishment will help improve bone development and metabolism.

in this study patients with chronic renal insufficiency and secondary osteoporosis or bone loss will be evaluated with traditional chinese medicine standard and allocated into kidney yin deficiency and kidney yang deficiency groups. in yin deficiency group, patients will be divided into zuogui granules treatment group and placebo group. in yang deficiency group, patients will be divided into yuogui granules treatment group and placebo group. all the patients will also accept basic treatment. after 3-month-treatment, we will detect blood urea nitrogen, creatinine, bone mineral density, bone metabolism markers including fgf23, 1,25(oh)2d3, osteocalcin, pth, balp, serum and urinal ca, p. we will also perform mirna array. the data before treatment and after treatment will be compared. the data of treatment groups and placebo groups will also be compared.

Eligibility criteria:
inclusion criteria: * chronic renal insufficiency * bone loss or osteoporosis * 30-50 years old * kidney yin or yang deficiency evaluated with traditional chinese medicine * be willing to and be able to join in the study and signed informed consent * have not accepted systematical treatment on bone loss or osteoporosis exclusion criteria: * allergies * secondary osteoporosis caused by other diseases. * postmenopausal women * mental illness or psychosis * patients with bone fracture and need surgery treatment * taking any medicine that will affect bone metabolism for a long time and can not stop * women during pregnant stage and breast-feed stage
study of efficacy of association of senna alexandrina mill and associations on functional intestinal constipation

Conditions: Constipation

Summary: the purpose of this study is to evaluate the efficacy of association of senna alexandrina mill (sena), cassia fistula l., tamarindus indica l., coriandrum sativum l., periandra mediterranea taub. in patients with functional constipation.

this is a phase iii trial, placebo-controlled with a parallel-group design.

Eligibility criteria:
inclusion criteria: * patients between 18-65 years with functional constipation by rome iiii criteria * in the opinion of the investigator the patient will adhere to the protocol * voluntary able to understand the nature and purpose of the study, including the risks and adverse effects and with intent to cooperate with the researcher and act in accordance with the requirements of the entire protocol, which was confirmed by signing the consent informed exclusion criteria: * hypersensitivity to any component * pregnant or lactating * abdominal pain of unknown etiology * suspected intestinal occlusion and sub-occlusion * suspected abdominal inflammatory conditions (as appendicitis, peritonitis, cystitis, endometritis) * crohn disease and colitis * suspected intestinal constipation due abdominal surgery, neurological disorders (as aganglionoses, parkinson disease, medullar tumor, stroke, multiple sclerosis), systemic sclerosis, multiple myeloma, scleroderma * subjects with congenital mega colon, anorectal congenital malformation, inflammatory bowel disease or intestinal carcinoma * history of mal-absorption diseases * history of anemia, weight loss or anal bleeding * history of hypothyroidism, hyperthyroidism and insulin-dependent diabetes mellitus * known of positive result for human immunodeficiency virus test * heart, liver, lung or kidney important condition * drug or alcohol dependence * knowledge or suspicion of malignancy * body mass index \< 18 * body mass index \> 30 * participation on any experimental study 12 months prior this study * familiar history of colon carcinoma or inflammatory disease * lack of adherence to the procedures of the protocol
study of bimatoprost gel on eyelash growth

Conditions: Madarosis; Hypotrichosis

Summary: a internally controlled, single-blinded, randomized controlled trial to investigate the use of bimatoprost eyelash gel on eyelash growth and appearance in breast cancer patients who suffer from madarosis (loss of eyelashes) due to the side effects of chemotherapy. ind and irb approval have been obtained.


Eligibility criteria:
inclusion criteria: * 18-80 yo females * madarosis or hypotrichosis (loss of eyelashes) due to chemotherapy used to treat breast cancer * only breast cancer patients exclusion criteria: * inability to follow up, apply gel * active eye/eyelid infection or inflammatory process * cancer not related to breast cancer, healthy patients * males
naps-ms: natalizumab effects on parameters of sleep in patients with multiple sclerosis experiencing fatigue or sleepiness

Conditions: Multiple Sclerosis, Relapsing-Remitting

Summary: the purpose of this study is to assess the impact of natalizumab (tysabri) therapy on sleep efficiency, total sleep time and sleep latency, in multiple sclerosis (ms) patients receiving natalizumab for 6 months relative to baseline.

natalizumab has been shown to positively impact fatigue and cognition. the mechanism by which this occurs is unknown. change in quality of sleep is one possible etiology of these findings. this study will help to elucidate the mechanisms that lead to reduced fatigue/sleepiness and less cognitive dysfunction in ms patients who go on natalizumab therapy. understanding these factors may help neurologists better differentiate between the different therapeutic options for ms and how they may impact symptoms that negatively affect quality of life.

Eligibility criteria:
inclusion criteria: * relapsing form of multiple sclerosis * able to give informed consent and committed to follow the protocol * edss from 0 to 6.0 * epworth sleepiness scale \> 9 or modified fatigue impact scale \> 30 or fatigue severity scale \> 4 * age range of 18 - 65 years of age * naïve to natalizumab * enrolled in the touch program exclusion criteria: * severe cognitive impairment * coexisting severe medical condition * inability to speak english or read * inability to give valid informed consent.
p300 brain computer interface keyboard to operate assistive technology

Conditions: Healthy; Amyotrophic Lateral Sclerosis; Neuromuscular Disease; Spinal Cord Injury; Cerebral Palsy

Summary: the purpose of this research is to develop tools enable people who are paralyzed to operate technology and access computers. these tools are called brain computer interfaces (bcis). bcis would let a person use brain signals to operate technology.

the purpose of this research is to develop tools to help people who are paralyzed. these tools are called brain computer interfaces (bcis). bcis would let a person use brain signals to operate technology. the investigators want to make a bci that can be used to operate commercially available technologies for communication, environmental control or computer access. the bci would replace a keyboard to let people operate these technologies without moving. however, the investigators need people to test the bci so that the investigators can see how well it can replace a keyboard. the investigators want to understand how well it can work so that the investigators can make it useful for people who are paralyzed. the investigators will ask people to use the bci to do things like make a communication system speak or type words on a computer.

Eligibility criteria:
inclusion criteria: * age 18 or older. * able to read text on a computer screen * able to understand and remember instructions concerning participation exclusion criteria: * unable give informed consent. * unable to understand and follow instructions. * have abnormal tone or uncontrolled movements in the head-and-neck that would interfere with eeg recordings. * known to have photosensitive epilepsy. * open head lesions or sores

Keywords: normal
competency-based approaches to community health

Conditions: Obesity, Childhood

Summary: this study is a family-centered, community-based intervention to prevent and treat childhood obesity among 3-5 year old children from undeserved communities. half of participants will receive a healthy lifestyle intervention and half of participants will receive a school-readiness intervention.

the complex multi-level determinants of childhood obesity necessitate a personalized approach. one of the main challenges to effective behavior change interventions is the complexity of the systems in which these behaviors are situated. namely, health behaviors are the result of the confluence of macro-level influences (e.g., the built environment, family, etc.) and micro-level influences (e.g., stress). furthermore, it is imperative that attempts to support healthy childhood growth consider the foundational contribution of a person's culture to their health behaviors, especially as children from traditionally underserved minorities are often hardest hit by obesity. this program will test a 15 week behavioral intervention followed by 3 months of coaching calls that uses principles from the learning sciences and health behavior change to help shape healthy behaviors in the context of family. the follow-up of the study will last 1 year. the content of the intervention will focus on health behavior change, including teaching goal-setting and self monitoring skills, as well as parenting strategies. the primary outcome of interest will be early childhood bmi trajectory over 1 year. additional measures will include survey data to measure parent and child health behaviors (e.g., diet, physical activity, sleep, media use) that are associated with obesity.

Eligibility criteria:
inclusion criteria: 1. three-to-five year old child 2. spanish or english-speaking 3. child's bmi ≥ 50% 4. parental commitment to participate in a year long study 5. consistent phone access 6. parent age ≥ 18 years 7. child completion of baseline data collection on height, weight, and waist circumference and all willing survey items completed by the parent 8. parents and children must be healthy (parents with controlled medical conditions will also be eligible). 9. dyad must be considered underserved which will be indicated by the parents self-reporting if they or someone in their household participate in one of these programs or services: tenncare, coverkids, wic, food stamps (snap), free and reduced price school lunch and breakfast, families first (tanf), and/or subsidized housing
positioning and gastric aspiration in ventilated premature infants

Conditions: Respiratory Aspiration of Gastric Contents

Summary: gastro-esophageal reflux and aspiration is a common problem in premature infants receiving mechanical ventilation. pepsin measured in tracheal aspirate (ta) emerged as a specific marker for aspiration. the objective of this study is to examine if ta pepsin will change when ventilated premature infants are positioned in two different positions; on their back vs. on their right side.


Eligibility criteria:
inclusion criteria: * infants born between 28 and 32 weeks gestational age * postnatal age \> 72 hours * tracheally intubated and receiving conventional mechanical ventilation * feeding enterally more than 20 ml per day. exclusion criteria: * neurological insult in the form of perinatal asphyxia (ph \<7, base deficit more than 12, apgar score at \< 3 at 5 minutes of life), intracranial hemorrhage grades 3 or 4 at 72 hours of age or periventricular leucomalacia * major congenital anomalies, or gastrointestinal anomalies such as tracheoesophageal fistula, or necrotizing enterocolitis , * receiving xanthine derivatives, h2 blockers, prokinetics, proton pump inhibitors or sedation